![]() IVUS core lab: Peter Fitzgerald, Stanford (Palo Alto) Economic core lab: David Cohen, Beth Israel (Boston) Industry sponsor: Cordis. Angiographic core lab: Jeffrey Popma, Brigham & Women’s Hospital. SIRIUS: Study Design Principal investigators: Martin Leon and Jeffrey Moses, Lenox Hill Study coordination: Richard Kuntz, Brigham & Women’s Hospital. Economic factors – index hospitalisation costs, length of stay, and repeat hospitalisations (for up to 12 months). Device success, lesion success, and procedure success (in-hospital). Angiographic binary restenosis ( 50% DS) at 8 months. ![]() Secondary: MACE at 1, 6, 9, 12m, and annually to 5 years. SIRIUS: Endpoints Primary: 9m Target Vessel Failure (cardiac death, MI, or TVR). SIRIUS: Purpose To assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITY™ in reducing target vessel failure in de novo native coronary artery lesions compared with the uncoated Bx stent.
0 Comments
Leave a Reply. |